Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Pre-Eclampsia Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Pre-Eclampsia Overview | 7 | 1 |
| Pipeline Products for Pre-Eclampsia Comparative Analysis | 8 | 1 |
| Pre-Eclampsia Therapeutics under Development by Companies | 9 | 1 |
| Pre-Eclampsia Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Pre-Eclampsia Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Pre-Eclampsia Products under Development by Companies | 13 | 1 |
| Pre-Eclampsia Products under Investigation by Universities/Institutes | 14 | 1 |
| Pre-Eclampsia Companies Involved in Therapeutics Development | 15 | 6 |
| A1M Pharma AB | 15 | 1 |
| Alnylam Pharmaceuticals, Inc. | 16 | 1 |
| Glenveigh Medical, LLC | 17 | 1 |
| LFB S.A. | 18 | 1 |
| Pluristem Therapeutics Inc. | 19 | 1 |
| VG Life Sciences, Inc. | 20 | 1 |
| Pre-Eclampsia Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 21 |
| A1M-001 Drug Profile | 30 | 2 |
| ALN-AGT Drug Profile | 32 | 1 |
| antithrombin (recombinant) Drug Profile | 33 | 2 |
| digoxin immune fab Drug Profile | 35 | 2 |
| PLX-PAD Drug Profile | 37 | 10 |
| RMC-035 Drug Profile | 47 | 1 |
| Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia Drug Profile | 48 | 1 |
| VG-1177 Drug Profile | 49 | 2 |
| Pre-Eclampsia Dormant Projects | 51 | 1 |
| Pre-Eclampsia Product Development Milestones | 52 | 10 |
| Featured News &Press Releases | 52 | 1 |
| Mar 22, 2016: A1M Pharma finalizes drug candidate for treating pre-eclampsia and files for substance patent | 52 | 1 |
| Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Pre-eclampsia | 52 | 1 |
| Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Pre-eclampsia and Indicates Their Superiority Over Other Cells | 53 | 1 |
| Dec 31, 2015: U.S. Food &Drug Administration Grants Orphan Drug Designation to Pluristem s PLX-PAD Cells for Treatment of Severe Pre-eclampsia | 54 | 1 |
| Sep 24, 2015: New clinical trial at SLU treats pre-eclampsia in second-trimester pregnancies | 54 | 1 |
| Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Pre-eclampsia | 55 | 2 |
| Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting | 57 | 1 |
| Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Pre-eclampsia (PRESERVE-1) | 57 | 1 |
| Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma s Treatment for Pre-eclampsia | 58 | 1 |
| Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Pre-eclampsia | 58 | 1 |
| Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Pre-eclampsia | 59 | 1 |
| Feb 20, 2014: Pluristem Submits FDA Orphan Drug Application for Pre-eclampsia | 60 | 1 |
| Nov 04, 2013: Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model | 60 | 2 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |
